| Infigratinib studied in …STUDIED_INderived24 of 24show fewer |
|---|
| → studied in | NCT02657486NA · completed BGJ398 in Non-Muscle-Invasive Urothelial Carcinoma of the Bladder · 24 trials list this drug (0 active) | — | — | Bladder Neoplasm,Malignant Bladder Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04233567Phase 2 · completed Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene Mutations · 24 trials list this drug (0 active) | — | — | Malignant Solid Neoplasm,Cholangiocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04504331Phase 1 · terminated Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer · 24 trials list this drug (0 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04424966early Phase 1 · terminated Infigratinib in Recurrent High-Grade Glioma Patients · 24 trials list this drug (0 active) | — | — | Glioblastoma,Glioma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04228042Phase 1/Phase 2 · terminated Infigratinib Before Surgery for the Treatment of Upper Tract Urothelial Cancer · 24 trials list this drug (0 active) | — | — | Renal Pelvis and Ureter Urothelial Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06206278Phase 2 · terminated Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ Adenocarcinoma · 24 trials list this drug (0 active) | — | — | Malignant Gastric Neoplasm,Gastroesophageal Junction Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03773302Phase 3 · terminated Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations · 24 trials list this drug (0 active) | — | — | Cholangiocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04197986Phase 3 · terminated Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations · 24 trials list this drug (0 active) | — | — | Renal Pelvis and Ureter Carcinoma,Urothelial Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02159066Phase 2 · completed LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma · 24 trials list this drug (0 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05514912Phase 2 · withdrawn Preoperative Nab-paclitaxel, Cisplatin, and Gemcitabine Chemotherapy With or Without Infigratinib Targeted Therapy for the Treatment of Resectable Intrahepatic Cholangiocarcinoma, The OPTIC Trial · 24 trials list this drug (0 active) | — | — | Intrahepatic Cholangiocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05510427Phase 1 · withdrawn Phase Ib Trial of Infigratinib In Combination With Atezolizumab And Bevacizumab for The Second-Line Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion/Amplification · 24 trials list this drug (0 active) | — | — | Malignant Liver Neoplasm,Cholangiocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02150967Phase 2 · terminated A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma · 24 trials list this drug (0 active) | — | — | Cholangiocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05222165Phase 1/Phase 2 · withdrawn Study With Infigratinib in Subjects With Advanced Solid and CNS Tumors or Recurrent or Progressive Low-Grade Glioma With Selected FGFR1-3 Alterations · 24 trials list this drug (0 active) | — | — | Solid Neoplasm,Central Nervous System Neoplasm,WHO Grade 2 Glioma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04972253Phase 1 · withdrawn Phase I BLASST-3 Trial · 24 trials list this drug (0 active) | — | — | Bladder Urothelial Carcinoma,Malignant Bladder Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05019794Phase 2 · unknown Infigratinib in Subjects With GC or GEJ With FGFR2 Amplification or Other Solid Tumors With Other FGFR Alterations · 24 trials list this drug (0 active) | — | — | Solid Neoplasm,Malignant Gastric Neoplasm,Gastroesophageal Junction Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03510455Phase 2 · terminated BGJ398 for the Treatment of Tumor-Induced Osteomalacia · 24 trials list this drug (0 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01928459Phase 1 · completed Phase 1b Trial of BGJ398/BYL719 in Solid Tumors · 24 trials list this drug (0 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01697605Phase 1 · completed A Phase I Study of Oral BGJ398 in Asian Patients · 24 trials list this drug (0 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02257541Phase 1/Phase 2 · completed BGJ398 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST) · 24 trials list this drug (0 active) | — | — | Gastrointestinal Stromal Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01975701Phase 2 · completed A Phase 2 Study of BGJ398 in Patients With Recurrent GBM · 24 trials list this drug (0 active) | — | — | Glioblastoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01004224Phase 1 · completed A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies · 24 trials list this drug (0 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02160041Phase 2 · terminated BGJ398 for Patients With Tumors With FGFR Genetic Alterations · 24 trials list this drug (0 active) | — | — | Hematopoietic and Lymphoid Cell Neoplasm,Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02706691Phase 2 · terminated BGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck Cancer · 24 trials list this drug (0 active) | — | — | Head and Neck Carcinoma,Head and Neck Squamous Cell Carcinoma,Malignant Nasopharyngeal Neoplasm+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02312804Phase 1 · withdrawn Ph Ib/BGJ398/Cervix and Other Solid Tumors · 24 trials list this drug (0 active) | — | — | Neoplasm,Malignant Cervical Neoplasm | 1 | Observed | clinicaltrials | graph → |